# Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

> **NCT05469464** · PHASE2 · COMPLETED · sponsor: **UNION therapeutics** · enrollment: 235 (actual)

## Conditions studied

- Atopic Dermatitis
- Skin Diseases

## Interventions

- **DRUG:** Orismilast modified release tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05469464
- **Lead sponsor:** UNION therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-11
- **Primary completion:** 2024-01-23
- **Final completion:** 2024-02-15
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469464, "Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05469464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*